Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Dermatologic 1CNS 1

Conditions

Melanoma 8Glioma 4Multiple Myeloma 3Thyroid Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Lymphoma 2Lung Neoplasms 2Hematologic Neoplasms 2Glioblastoma 2Colorectal Neoplasms 2Astrocytoma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Spinocerebellar Degenerations 1Sarcoma 1Refractory Differentiated Thyroid Gland Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neurocytoma 1Neuroblastoma 1Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation 1

Interventions

Carboplatin 121pembrolizumab 119Pemetrexed 102Cisplatin 76Paclitaxel 56osimertinib 52Nivolumab 50Docetaxel 50durvalumab 47Specimen Handling 37Gemcitabine 34Magnetic Resonance Spectroscopy 33Radiosurgery 27Cetuximab 26130-nm albumin-bound paclitaxel 26atezolizumab 25Radiotherapy 20Ipilimumab 19Drug Therapy 19Bevacizumab 19cemiplimab 17amivantamab 17Taxes 16Ramucirumab 13alectinib 12tislelizumab 11lazertinib 11Leucovorin 11Fluorouracil 11Radiation 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × dabrafenib × 90 days × Clear all
NCT03340506 2026-04-20

Dabrafenib and/or Trametinib Rollover Study

Novartis

Phase 4 Recruiting
100 enrolled
CNSDermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Glioma, Lung Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡